Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 2, 2000, Pages 114-121

  Dingemanse, Jasper ^a,b   Soubrouillard, Catherine ^a,b   Paris, Jérôme ^a,b   Pisano, Pascale ^a,b   Blin, Olivier ^a,b  

^a Medicines Company   (Switzerland)

^b Centre De Pharmacologie Clinique Et d'Evaluations Therapeutiques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL; CAPRYLOCAPRYOL MACROGOLGLYCERIDE DERIVATIVE; CARBOXYMETHYLENEOXY TYROLYLGLYCINAMIDE SEROTONIN; IS 159; SEROTONIN 1B AGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG TOLERABILITY; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MIGRAINE; MUSCLE WEAKNESS; NEUROTOXICITY; NORMAL HUMAN; NOSE OBSTRUCTION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINORRHEA; SNEEZING; SWEATING; TASTE DISORDER; THROAT DISEASE;

ADMINISTRATION, INHALATION; ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FATTY ACIDS; GLYCERIDES; HUMANS; INDOLES; MALE; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SURFACE-ACTIVE AGENTS;

EID: 0033837617     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.108196     Document Type: Article

References (30)

1. Diagnosis and management of migraine
2. Burden of migraine in the United States. Disability and economic costs
3. Present and future of 5-HT receptor agonists as antimigraine drugs
4. Advances in migraine therapy - 5-HT receptor subtype-specific agonist drugs
5. Pharmacology of triptans
6. Sumatriptan: An updated review of its use in migraine
7. Antimigraine drugs
8. 5-HT(1D) receptors: Pharmacology and therapeutic potential
9. Nasal drug delivery: Trends and perspectives
10. Studies on the promoting effects of medium chain fatty acid salts on the nasal absorption of insulin in rats
11. Absorption enhancers in nasal drug delivery: Efficacy and safety
12. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity
13. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method
14. Migraine without aura
15. Intranasal drug delivery: Potential advantages and limitations from a clinical pharmacokinetic perspective
16. Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate
17. The use of a radiolabelled saccharin solution to monitor the effect of the preservatives thiomersal, benzalkonium chloride and EDTA on human nasal clearance
18. Safety, tolerability, and pharmacoldnetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses
19. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration
20. Human pharmacokinetics of dihydroergotamine administrated by nasal spray
21. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
22. Sumatriptan. Clinical pharmacokinetics
23. Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks
24. Chitosan as a novel nasal delivery system for peptide drugs
25. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption
26. Intranasal administration of diazepam aiming at the treatment of acute seizures; clinical trials in healthy volunteers
27. Cardiovascular safety of 5-HT(1B/1D) agonists - Is there a cause for concern?